Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “dexlansoprazole” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 20
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 20 pipeline programs matching "dexlansoprazole" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

20 results for “dexlansoprazole” Back to intelligence hub

Search results

  1. Dexlansoprazole

    Takeda

    Heartburn

    phase 3 small molecule completed

    1 trial
  2. Dexlansoprazole

    Takeda

    Erosive Esophagitis

    phase 3 small molecule terminated

    2 trials
  3. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    2 trials
  4. Dexlansoprazole MR

    Takeda

    Esophagitis, Reflux

    phase 3 small molecule completed

    5 trials
  5. Dexlansoprazole MR

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    4 trials
  6. Dexlansoprazole MR QD

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    1 trial
  7. Dexlansoprazole

    Takeda

    Barrett's Esophagus

    phase 2 small molecule terminated

    1 trial
  8. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux Disease (GERD)

    phase 2 small molecule active

    1 trial
  9. 30 mg dexlansoprazole capsules manufactured at TOB

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials
  10. Dexlansoprazole

    Takeda

    Homeostasis

    phase 1 small molecule completed

    1 trial
  11. Dexlansoprazole

    Takeda

    Pediatric Gastroesophageal Reflux Disease

    phase 1 small molecule terminated

    1 trial
  12. Dexlansoprazole

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  13. Dexlansoprazole Delayed Release Orally Disintegrating Tablets

    Takeda

    Bioavailability

    phase 1 small molecule completed

    1 trial
  14. Dexlansoprazole Injection

    The First People's Hospital of Lianyungang

    Effect of Drugs

    phase 1 small molecule active

    1 trial
  15. Dexlansoprazole MR

    Takeda

    Gastroesophageal Reflux

    phase 1 small molecule completed

    1 trial
  16. dexlansoprazole injection

    The First People's Hospital of Lianyungang

    Safety Issues

    phase 1 small molecule completed

    1 trial
  17. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux Disease

    approved small molecule completed

    4 trials
  18. Dexlansoprazole 60 MG

    Takeda

    GERD

    approved small molecule completed

    1 trial
  19. dexlansoprazole

    Takeda

    Laryngopharyngeal Reflux

    approved small molecule active

    1 trial
  20. Dexlansoprazole

    Takeda

    Laryngo-pharyngeal Reflux

    small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.